Malaz Abutarif

For those interested in Physiologically Based Biopharmaceutics Modeling (PBBM) please check out our recently published article from the 2023 PBBM workshop. It proposes best practices for measuring solubility, dissolution, precipitation and permeability for parameterizing PBBMs, summarizes breakout sessions, and shares PBBM case studies. https://lnkd.in/gda_HH4F

95

2 Comments

Excited to share the latest feature in our "Partnering Spotlight" series, where we share some of the connections we are building to foster scientific innovation in healthcare. In this edition, our very own Neha Kaushal sits down with Daniel Anderson, Professor of Chemical Engineering at MIT, to discuss the potential of innovative #mRNA applications in vaccines and novel treatments for genetic diseases. Check out the video to learn more about our collaboration! https://lnkd.in/eHwpyjeY #vaccines #immunoscience

40

1 Comment

Transitions. Did you "cut your teeth" in medicinal chemistry and drug discovery at a Big Pharma, and then transition to a senior leadership position at a biotech or start-up? If so, I invite you to contribute a guest editorial at JMC and describe the experience, pros/cons and other factors that led to your move. #JMEDCHEM

80

2 Comments

At the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference held in Seoul, there was a strong emphasis on creating contingency plans to tackle geopolitical uncertainty. This topic was highlighted across several panel discussions. https://gag.gl/s8brdw

3

The BAT4406F team and its clinical collaborators published the Phase 1 study exploring BAT4406F in Neuromyelitis Optica Spectrum Disorders patients. BAT4406F is currently in a Phase 2/3 in China and looks like a very promising new therapy for #NMOSD patients. https://lnkd.in/eKsUYrig #CD20 #autoimmune #ophthalmology #raredisease #FIH

14

New publication online. We conducted this physician survey to explore the motivations and considerations of hematologists in Japan when making treatment decisions for chronic lymphocytic leukemia (CLL). In conclusion, our survey underscored the importance of evidence-based treatments and the need for further promotion of such treatments to ensure informed decision-making among physicians. https://lnkd.in/g7VXbhkm

13

⚕ Potentially curative gene therapies such as these will play a pivotal role in relative market positioning and overall treatment landscape compared to legacy interventions. ✅ Just announced, a new #GeneTherapy US FDA approval: Pfizer scores for their 'one-time' treatment for adults with moderate to severe Hemophilia B, BEQVEZ (fidanacogene elaparvovec-dzkt). 💉 This single-dose treatment intends to replace the need for prophylactic/ongoing administration of blood clotting factors. 🤔 For therapeutic areas seeing an uptick in forthcoming gene therapies in development (or, having already launched), how might these innovations affect the #BrandStrategy moving forward? #Innovation #RareDiseases #Strategy #CompetitiveIntelligence #MarketIntelligence #Pharma #Healthcare https://lnkd.in/eVk38c7P

7

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab #Merck #Clinicaldevelopment #Clinicaltrials

7

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

BSI Immune Therapies 2024: Key Insights and Innovations Engaging Talks: Discussions across immune-oncology, autoimmunity, and inflammation sparked cross-disciplinary insights. Breakout Focus Sessions: Topics like innate immunity and checkpoint inhibitors fostered dynamic small-group debates on drug discovery, clinical trials, and patient care perspectives. Therapeutic Breakthroughs: From IL-23 pathway research to oncolytic viral immunotherapy for solid tumours, innovation continues to translate blue-sky research into real-world treatments. Biomarker Strategies: Emphasised their pivotal role in advancing from 'imprecision' medicine to tailored therapies for arthritis and IBD. The British Society for Immunology deserves praise for driving impactful discussions. Excited for future conferences! To read more, the link is in the first comment

25

1 Comment

CinRx Pharma just shared data on its two innovative assets to tackle #obesity at the recent 2024 #ObesityWeek Conference: 🔬 A long-acting GDF-15 analog CIN-109 and a selective PYY3-36 analog CIN-110 ✨Both demonstrated promising tolerability and weight loss in early-stage studies in PI single (-110) and multiple (-109) ascending dose studies. ⏩ From the #strategic horizon, and the expected strong growth rates in this category, more MOAs are needed beyond the GLP1 agonists. As we saw this past year and late last year, the main manufacturers have been peppered with supply, manufacturing, and altogether supply chain issues, which made keeping up with demand quite challenging and does not make for a sustaining business model. I hope that patients are able to access more treatment options by way of more modalities. #2024ObesityWeek #Obesity #antiobesity #GLP1 #NovoNordisk #Lilly #ELiLilly #Biotech #CinRx #CinRxPharma #CinFinaPharma #ClinicalAffairs #MedicalAffairs #Pharma #Healthcare

6

3 Comments

If you missed our poster presentation at #ASCO24 titled "Feasibility and Utilization of Electronic Patient-Reported Outcome Measures for Lung Cancer in Routine Clinical Care," in collaboration with our partners at the University of North Carolina and Takeda Pharmaceuticals, below are the key findings.   This study explored the feasibility of standardizing PRO measures among patients with lung cancer in US clinical practice. Using the ePRO and alerts data collected from Carevive RSM, we explored patient engagement, measured by survey compliance and data completeness, as well as clinical team engagement measured by the platform utilization time, time to alert response, and clinical action taken when patients reported moderate/severe symptoms (Figures 2 and 4). ✅ Results support the feasibility of integrating a standard set of multi-domain ePRO measures, comparable in breadth and scope to the Health Outcomes Observatory (H2O) Core Outcomes Set, into routine lung cancer care. ✅ Patient engagement was high, as indicated by survey compliance and completeness, particularly in the first 5 weeks of enrollment. The median survey follow-up was 8 weeks, with 85% median compliance over that time. ✅ The clinical team's engagement was high, as indicated by frequent usage of the platform and timely response to symptom alerts, with a median of 20 hours and 69.3% addressed in less than 2 days. ✅ Findings support the value of remote symptom alerts, when integrated into clinical workflow, for enhancing the timeliness of patient and care team communications, and timely addressing of symptoms to optimize care. Read more of the presentation here: https://lnkd.in/esFXwb69 Aaron Galaznik Emelly Rusli Keri Collette Mordecai Kramer Bruno Lempernesse #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

2

Learn how we collaborated with Checkpoint Therapeutics to develop a quantitative systems pharmacology model to support dose justification for anti-PD-L1 clinical candidate CK-301 in oncology patients. Read the case study at: https://lnkd.in/em3Dd3KH #oncology #drugdesign #drugdevelopment #mechanisticmodeling #qsp

18

Breaking barriers in ADC development: What’s next? 🔎 Antibody-drug conjugates are no longer just a concept – they’re revolutionizing cancer therapy with precision-targeted treatments. However, their success hinges on robust development strategies. Allucent explores how improved analytical methods, scalable manufacturing, and compliance with global regulatory standards are key to unlocking the full potential of ADCs. 🚀 By understanding the complex interplay of science, strategy, and regulation, biotech companies can navigate the challenges of bringing ADCs from the lab to the clinic. Dive into Allucent’s roadmap for clinical success and learn how ADCs are evolving to meet the unmet needs in oncology. 🔬 Full article below ⬇️ https://lnkd.in/dmUUXcdB #ADCtherapies #oncologyinnovation #cancerresearch #targetedtherapies #precisionmedicine #bispecificADCs #pharmabreakthroughs #drugdevelopment 

9